Loading...
•
Dec 31, 2019
Bausch Health Q4 2019 Earnings Report
Bausch Health reported revenue growth and adjusted EBITDA increase, driven by Salix and Bausch + Lomb/International segments.
Key Takeaways
Bausch Health Companies Inc. announced its fourth-quarter and full-year 2019 financial results, demonstrating consistency and durability with revenue growth and strong performance in the Salix and Bausch + Lomb/International segments. The company delivered total company reported revenue growth of 5% in the fourth quarter and 3% for the full year of 2019.
Revenues of $2.224 Billion
GAAP Cash Generated from Operations of $234 Million
GAAP Net Loss of $1.516 Billion
Adjusted EBITDA (non-GAAP) of $898 Million
Revenue by Segment
Forward Guidance
Bausch Health provided guidance for the full year of 2020, as follows: • Full-Year revenues in the range of $8.65 - $8.85 billion • Full-Year Adjusted EBITDA (non-GAAP) in the range of $3.50 - $3.65 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...